Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

A comparative analysis of blood pressure in HIV-infected patients versus uninfected controls residing in Sub-Saharan Africa: a narrative review

Abstract

Elevated blood pressure (BP) is an important risk factor for cardiovascular disease and mortality in Sub-Saharan Africa (SSA). We reviewed the literature comparing BP in treated HIV-infected populations against untreated and/or uninfected controls from SSA. We conducted a narrative review through PubMed and EBSCO Discovery Service to determine estimates of raised BP and hypertension in HIV-infected patients versus untreated/uninfected controls (1 January 2005 to 31 July 2019 and 9 May 2020). We included 19 eligible studies that compared treated HIV-infected with untreated and/or uninfected controls. In studies comparing treated HIV-infected patients to uninfected controls, studies including 6882 (56.30%) and 21,819 (79.2%) participants reported lower BP and hypertension prevalence, respectively in HIV-infected patients; whereas studies including 753 (6.16%) and 3553 (12.9%) participants showed a higher BP and hypertension prevalence. Lastly, 4588 (37.54%) and 2180 (7.91%) participants showed no difference in BP and the prevalence of hypertension. When comparing BP of treated versus untreated HIV-infected patients, studies including 5757 (44.2%) patients reported lower BP in treated patients; while studies with 200 (1.53%) patients showed higher BP and 7073 (54.28%) showed no difference in BP. For hypertension status, studies with 4547 (74.5%) patients reported a lower prevalence of hypertension in treated patients; whereas studies with 598 (9.80%) patients showed higher prevalence; and 959 (15.7%) no difference in prevalence between treated versus untreated HIV-infected patients. In studies conducted in Sub-Saharan Africa, the majority of the findings indicate lower blood pressure and/or prevalence of hypertension in treated HIV-infected individuals compared to untreated and uninfected controls.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Flow chart of the literature selection process.
Fig. 2: Do HIV-infected patients using ART have higher blood pressure (or prevalence of hypertension) than uninfected controls and untreated HIV-infected patients?

Similar content being viewed by others

Data availability

All data generated or analyzed during this study are included in this published article (and its Supplementary Information Files).

References

  1. World Health Organisation (WHO). Non-communicable diseases progress monitor; 2017. https://apps.who.int/iris/bitstream/handle/10665/258940/9789241513029eng.pdf;jsessionid=1C1BA5558A13F32641747BB22410DF56?sequence=1. Accessed 11 Feb 2019.

  2. Nguyen KA, Peer N, Mills EJ, Kengne AP. Burden, determinants, and pharmacological management of hypertension in HIV-positive patients and populations: a systematic narrative review. AIDS Rev. 2015;17:83–95.

    PubMed  Google Scholar 

  3. Cappuccio FP, Miller MA. Cardiovascular disease and hypertension in sub-Saharan Africa: burden, risk and interventions. Int J Emergen Med. 2016;11:299–305.

    Google Scholar 

  4. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS Monitoring 2019: Indicators for monitoring the 2016 Political Declaration on Ending AIDS; 2019. http://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf. Accessed 11 Feb 2019.

  5. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS data 2017; 2017. http://www.who.int/hiv/pub/arv/global-AIDS-update-2016_en.pdf. Accessed 7 May 2019.

  6. Maher D, Ford N, Unwin N. Priorities for developing countries in the global response to non-communicable diseases. Glob Health. 2012;8:14–6.

    Google Scholar 

  7. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global HIV statistics; 2017. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Accessed 6 May 2019.

  8. Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the Global AIDS Epidemic; 2010. http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf. Accessed 12 Feb 2019.

  9. Cerrato E, Calcagno A, D’Ascenzo F, Biondi-Zoccai G, Mancone M, Marra WG, et al. Cardiovascular disease in HIV patients: from bench to bedside and backwards. Open Heart. 2015;2:e000174–8.

    PubMed  PubMed Central  Google Scholar 

  10. van Zoest RA, Wit FW, Kooij KW, van der Valk M, Schouten J, Kootstra NA, et al. Higher prevalence of hypertension in HIV-1-infected patients on combination antiretroviral therapy is associated with changes in body composition and prior stavudine exposure. Clin Infect Dis. 2016;63:205–13.

    PubMed  Google Scholar 

  11. Mosepele M, Hemphill LC, Moloi W, Moyo S, Nkele I, Makhema J, et al. Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls. PLoS ONE. 2017;12:e0179994–8.

    PubMed  PubMed Central  Google Scholar 

  12. Osegbe ID, Soriyan OO, Ogbenna AA, Okpara HC, Azinge EC. Risk factors and assessment for cardiovascular disease among HIV-positive patients attending a Nigerian tertiary hospital. Pan Afr Med J. 2016;23:2–9.

    Google Scholar 

  13. Mbunkah HA, Meriki HD, Kukwah AT, Nfor O, Nkuo-Akenji T. Prevalence of metabolic syndrome in human immunodeficiency virus-infected patients from the South-West region of Cameroon, using the adult treatment panel III criteria. Diabetol Met Syndr. 2014;6:1–14.

    Google Scholar 

  14. Bergersen B, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis. 2003;22:731–6.

    CAS  PubMed  Google Scholar 

  15. Mattana J, Siegal FP, Sankaran RT, Singhal PC. Absence of age-related increase in systolic blood pressure in ambulatory patients with HIV infection. Am J Med Sci. 1999;317:232–7.

    CAS  PubMed  Google Scholar 

  16. Ogunmola OJ, Oladosu OY, Olamoyegun AM. Association of hypertension and obesity with HIV and antiretroviral therapy in a rural tertiary health center in Nigeria: a cross-sectional cohort study. Vasc Heal Risk Manag. 2014;10:129–37.

    Google Scholar 

  17. Feigl AB, Bloom DE, Danaei G, Pillay D, Salomon JA, Tanser F, et al. The effect of HIV and the modifying effect of anti-retroviral therapy (ART) on body mass index (BMI) and blood pressure levels in rural South Africa. PLoS ONE. 2016;11:1–15.

    Google Scholar 

  18. Nduka CU, Stranges S, Bloomfield GS, Kimani PK, Achinge G, Malu AO, et al. A plausible causal link between antiretroviral therapy and increased blood pressure in a sub-Saharan African setting: a propensity score-matched analysis. Int J Cardiol. 2016;220:400–7.

    PubMed  Google Scholar 

  19. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metabol. 2007;92:2506–12.

    CAS  Google Scholar 

  20. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens. 2003;21:1377–82.

    CAS  PubMed  Google Scholar 

  21. Dillon DG, Gurdasani D, Riha J, Ekoru K, Asiki G, Mayanja BN, et al. Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol. 2013;42:1754–71.

    PubMed  Google Scholar 

  22. Hejazi N, Huang MS, Lin KG, Choong LC. Hypertension among HIV-infected adults receiving highly active antiretroviral therapy (HAART) in Malaysia. Glob J Health Sci. 2014;6:58–71.

    Google Scholar 

  23. Medina-Torne S, Ganesan A, Barahona I, Crum-Cianflone NF. Hypertension is common among HIV-infected persons, but not associated with HAART. J Int Assoc Physician AIDS Care 2012;11:20–5.

    Google Scholar 

  24. Crane H, Grunfeld, Harrington RD, Kitahata MM. Lipoatrophy and lipohypertrophy are independently associated with hypertension. HIV Med. 2009;10:496–503.

    PubMed  PubMed Central  Google Scholar 

  25. Okello S, Ueda P, Kanyesigye M, Byaruhanga E, Kiyimba A, Amanyire G, et al. Association between HIV and blood pressure in adults and role of body weight as a mediator: cross-sectional study in Uganda. J Clin Hypertens. 2017;19:1181–91.

    Google Scholar 

  26. Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59:1787–97.

    CAS  PubMed  Google Scholar 

  27. Guihot A, Tubiana R, Breton G, Marcelin AG, Samri A, Assoumou L, et al. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS. 2010;24:614–7.

    PubMed  Google Scholar 

  28. Chow DC, Souza SA, Chen R, Richmond-Crum SM, Grandinetti A, Shikuma C. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials. 2003;4:411–6.

    PubMed  Google Scholar 

  29. Keates AK, Mocumbi AO, Ntsekhe M, Sliwa K, Stewart S. Cardiovascular disease in Africa: epidemiological profile and challenges. Nat Rev Cardiol. 2017;14:273–6.

    PubMed  Google Scholar 

  30. Currier J. Epidemiology of cardiovascular disease and risk factors in HIV-infected patients; 2019. https://www.uptodate.com/contents/epidemiology-of-cardiovascular-disease-and-risk-factors-in-hiv-infected-patients. Accessed 24 May 2019.

  31. Peeters M. The genetic variability of HIV-1 and its implications. Transfus Clin Biol. 2001;8:222–4.

    CAS  PubMed  Google Scholar 

  32. Republic of South Africa National Department of Health (DoH). Clinical Guidelines for the Management of HIV in Adults, Pregnancy, Adolescents, Children, Infants and Neonates; 2019. https://sahivsoc.org/Files/2019%20ART%20Guideline%2028042020%20pdf.pdf. Accessed 2 June 2020.

  33. European AIDS Clinical Society (EACS). European Guidelines for the treatment of people living with HIV (PLWH) in Europe; 2019. https://www.eacsociety.org/files/guidelines-10.0_final_2_2.pdf. Accessed 2 June 2020.

  34. Manner IW, Baekken M, Oektedalen O, Os I. Hypertension and antihypertensive treatment in HIV-infected individuals. A longitudinal cohort study. Blood Press. 2012;21:311–9.

    PubMed  Google Scholar 

  35. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Kelly C, Mwandumba HC, Heyderman RS, Jambo K, Kamng’ona R, Chammudzi M, et al. HIV-related arterial stiffness in malawian adults is associated with the proportion of PD-1–expressing CD8+ T cells and reverses with antiretroviral therapy. J Infect Dis. 2019;219:1948–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. van Heerden A, Barnabas RV, Norris SA, Micklesfield LK, van Rooyen H, Celum C. High prevalence of HIV and non‐communicable disease (NCD) risk factors in rural KwaZulu-Natal, South Africa. J Int AIDS Soc. 2017;20:1–8.

    Google Scholar 

  38. Edwards JK, Bygrave H, Van den Bergh R, Kizito W, Cheti E, Kosgei RJ, et al. HIV with non-communicable diseases in primary care in Kibera, Nairobi, Kenya: characteristics and outcomes 2010–2013. Trans R Soc Trop Med Hyg. 2015;109:440–6.

    PubMed  Google Scholar 

  39. Malaza A, Mossong J, Bärnighausen T, Newell ML. Hypertension and obesity in adults living in a high HIV prevalence rural area in South Africa. PLoS ONE. 2012;7:e47761–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Manne-Goehler J, Montana L, Gómez-Olivé FX, Gómez-Olivé FX, Rohr J, Harling G, et al. The ART advantage: healthcare utilization for diabetes and hypertension in rural South Africa. J Aids. 2017;75:561–8.

    CAS  Google Scholar 

  41. Fourie C, Schutte AE, Smith W, Kruger A, van Rooyen JM. Endothelial activation and cardiometabolic profiles of treated and never-treated HIV infected Africans. Atherosclerosis. 2015;240:154–60.

    CAS  PubMed  Google Scholar 

  42. Benzekri NA, Seydi M, Doye IN, Toure M, Sy MP, Kiviat NB, et al. Correction: Increasing prevalence of hypertension among HIV-positive and negative adults in Senegal, West Africa, 1994-2015. PLoS ONE. 2019;14:e0212250–8.

    PubMed  PubMed Central  Google Scholar 

  43. Kamtchum-Tatuene J, Mwandumb H, Al-Bayati Z, Flatley J, Griffiths M, Solomon T, et al. HIV is associated with endothelial activation despite ART, in a sub-Saharan African setting. Neurol Neuroimmunol Neuroinflamm. 2018;6:e531–6.

    PubMed  PubMed Central  Google Scholar 

  44. Geldsetzer P, Feigl AB, Tanser F, Gareta D, Pillay D, Bärnighausen T, et al. Population-level decline in BMI and systolic blood pressure following mass HIV treatment: evidence from rural KwaZulu-Natal. Obesity. 2017;25:200–6.

    CAS  PubMed  Google Scholar 

  45. Msoka TF, Van Guilder GP, Smulders YM, van Furth M, Bartlett JA, van Agtmael MA, et al. Antiretroviral treatment and time since HIV-1 diagnosis are associated with large artery stiffness in sub-Saharan African HIV-1 patients. Artery Res. 2016;16:34–41.

    Google Scholar 

  46. Peck RN, Shedafa R, Kalluvya S, Downs JA, Todd J, Suthanthiran M, et al. Hypertension, kidney disease, HIV and antiretroviral therapy among Tanzanian adults: a cross-sectional study. BMC Med. 2014;12:1–11.

    Google Scholar 

  47. Dimala CA, Atashili J, Mbuagbaw JC, Wilfred A, Monekosso GL. Prevalence of hypertension in HIV/AIDS patients on highly active antiretroviral therapy (HAART) compared with HAART-naïve patients at the Limbe Regional Hospital, Cameroon. PLoS ONE. 2016;11:1–11.

    Google Scholar 

  48. Pangmekeh PJ, Mbunka MA, Simo G, Tayong G, Samuel NC. Association between highly active antiretroviral therapy (HAART) and hypertension in persons living with HIV/AIDS at the Bamenda regional hospital, Cameroon. Pan Afr Med J. 2019;33:1–11.

    Google Scholar 

  49. Goedecke JH, Utzschneider K, Faulenbach MV, Rizzo M, Berneis K, Spinas GA, et al. Ethnic differences in serum lipoproteins and their determinants in South African women. Metabolism. 2010;59:1341–50.

    CAS  PubMed  Google Scholar 

  50. Nduka C, Stranges S, Sarki AM, Kimani PK, Uthmanet OA. Evidence of increased blood pressure and hypertension risk among people living with HIV on antiretroviral therapy: a systematic review with meta-analysis. J Hum Hypertens. 2016;30:355–62.

    CAS  PubMed  Google Scholar 

  51. Thiébaut R, El-Sadr WM, Friis-Møller N, Rickenbach M, Reiss P, Monforte AD, et al. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther. 2005;10:811–23.

    PubMed  Google Scholar 

  52. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS. 2006;20:1019–26.

    CAS  PubMed  Google Scholar 

  53. Barth RE, van der Loeff M, Schuurman R, Hoepelman A, Wensing A. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10:155–66.

    CAS  PubMed  Google Scholar 

  54. Meintjes G, Moorhouse MA, Carmona S, Davies N, Dlamini S, van Vuuren C, et al. Adult antiretroviral therapy guidelines 2017. South Afr J HIV Med. 2017;18:1–24.

    Google Scholar 

  55. Kwarisiima D, Atukunda M, Owaraganise A, Chamie G, Clark T, Kabami J, et al. Hypertension control in integrated HIV and chronic disease clinics in Uganda in the SEARCH study. BMC Public Health. 2019;19:1–10.

    Google Scholar 

  56. Masenga SK, Hamooya BM, Nzala S, Kwenda G, Heimburger DC, Mutale W, et al. Patho-immune mechanisms of hypertension in HIV: a systematic and thematic review. Curr Hypertens Rep. 2019;21:1–19.

    CAS  Google Scholar 

  57. Xu Y, Chen X, Wang K. Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis. J Am Soc Hypertens. 2017;11:530–40.

    PubMed  Google Scholar 

  58. Fahme SA, Bloomfield GS, Peck R. Hypertension in HIV-infected adults: novel pathophysiologic mechanisms. Hypertension. 2018;72:44–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non–AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210:1248–59.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Reiner AP, Lange EM, Jenny NS, Chaves PH, Ellis J, Li J, et al. Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arterioscler Thromb Vasc Biol. 2013;33:158–64.

    CAS  PubMed  Google Scholar 

  61. Sarfo FS, Nichols M, Arti Singh A, Hardy Y, Norman B, Mensah G, et al. Characteristics of hypertension among people living with HIV in Ghana: impact of new hypertension guideline. J Clin Hypertens. 2019;21:838–50.

    CAS  Google Scholar 

  62. Yu I, Tse S. Workshop 6-sources of bias in cross-sectional studies; summary on sources of bias for different study designs. Hong Kong Med J. 2012;18:226–7.

    PubMed  Google Scholar 

  63. Lu CY. Observational studies: a review of study designs, challenges and strategies to reduce confounding. Int J Clin Pract. 2009;63:691–7.

    CAS  PubMed  Google Scholar 

  64. Republic of South African National Department of Health (DoH). The South African antiretroviral treatment guidelines in 2010; 2010. https://sahivsoc.org/Files/ART%20Guidelines%2015052015.pdf. Accessed 12 Feb 2019.

Download references

Acknowledgements

AES received financial support from the South African National Research Foundation (SARChI GUN86895) and the South African Medical Research Council. Edith Phalane received financial support from Department of Science and Technology/ National Research Foundation and TATA Africa Holdings.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carla M. T. Fourie.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Phalane, E., Fourie, C.M.T., Mels, C.M.C. et al. A comparative analysis of blood pressure in HIV-infected patients versus uninfected controls residing in Sub-Saharan Africa: a narrative review. J Hum Hypertens 34, 692–708 (2020). https://doi.org/10.1038/s41371-020-0385-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41371-020-0385-6

This article is cited by

Search

Quick links